Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Registration Number
- NCT00147953
- Lead Sponsor
- University of Cologne
- Brief Summary
This study aims to assess the short term efficacy of a combination of rituximab and low-dose radiotherapy in patients with non-Hodgkin's lymphoma.
- Detailed Description
Rituximab and low-dose total-nodal irradiation both have shown promising activity in patients with NHL. Moreover, the radiolabelled antibody Zevalin has been approved for the treatment of relapsed NHL. The patients in this study have a poor prognosis. The treatment strategy aims to control the disease and to ameliorate disease related symptoms with minimal toxicity. Both, rituximab and low-dose radiotherapy are associated with minor toxicity if applied alone.
The primary objective of the study is therefore to assess the short term efficacy of a combination of rituximab and low-dose radiotherapy in patients with non-Hodgkin's lymphoma.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
- B-cell non-Hodgkin's lymphoma
- At least one prior antitumor therapy
- ECOG performance status 0-2
- No major organ dysfunction
- Written informed consent
- The following histologies are excluded: Burkitt's lymphoma, mantle-cell lymphoma, primary CNS-lymphoma, HIV-associated lymphoma
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Overall response rate (complete and partial response rate)
- Secondary Outcome Measures
Name Time Method Toxicity Time to progression Response duration Quality-of-Life
Trial Locations
- Locations (1)
University of Cologne
🇩🇪Cologne, NRW, Germany